Glepaglutide Therapy for Short Bowel Syndrome Intestinal Failure
Background: Glepaglutide is a long-acting glucagon-like peptide-2 analog, developed to improve intestinal absorption (Larsen BD et al. J Med Chem. 2025). We report the efficacy and safety of glepaglutide therapy in short bowel syndrome (SBS) patients with intestinal failure (IF).
Authors
- M Hansen (ORCID: https://orcid.org/0000-0003-1305-3382)
- David F. Mercer (ORCID: https://orcid.org/0000-0003-1557-1773)
- Georg Lamprecht (ORCID: https://orcid.org/0000-0003-0997-3135)
- Francisca Joly (ORCID: https://orcid.org/0000-0002-9341-7133)
- Farooq Rahman (ORCID: https://orcid.org/0000-0002-1997-5866)
- Geert Wanten
- Thor SS Nielsen
- Marek Kunecki (ORCID: https://orcid.org/0000-0002-2163-5131)
- Lykke Bjerglund Graff
- Tim Vanuytsel (ORCID: https://orcid.org/0000-0001-8728-0903)
- Palle Bekker Jeppesen (ORCID: https://orcid.org/0000-0001-9680-6938)
- Sukanya Subramanian
- Ulrich F. Pape
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- Radboud University Nijmegen (NL)
- Georgetown University (US)
- Hôpital Beaujon (FR)
- Bispebjerg Hospital (DK)
- MedStar Georgetown University Hospital (US)
- Rigshospitalet (DK)
- Radboud University Medical Center (NL)
- Zealand Pharma (Denmark) (DK)
- Asklepios (DE)
- University College London (GB)
- University of Rostock (DE)
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100080
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00